Skip to content

Here’s when Palantir stock could hit $30

Here’s when Palantir stock could hit $30
Elmaz Sabovic

Palantir Technologies (NYSE: PLTR), initially funded by the CIA and other intelligence agencies, is now making significant strides in the private sector, positively impacting its stock performance. The company had an IPO in 2020 at $10 per share, and Palantir’s stock price today trades at just under $22.

Founded in 2003 for government risk assessment analytics, Palantir expanded into business analytics due to the vast data businesses generate and the more significant market opportunity. Although most revenue still comes from the public sector, the private sector’s potential is substantial.

In the first quarter, government sales made up 52% of Palantir’s $634 million revenue, with growth increasing from 11% to 16%. Commercial revenue decreased from 70% to 40%. Despite substantial growth, Wall Street questions the sustainability of private sector expansion and whether Palantir stock can reach a $30 valuation.

Most analysts don’t see much of an upside for PLTR

Despite Palantir Technologies consistently beating analysts’ earnings expectations, Wall Street remains skeptical about PLTR stock’s potential surge over the next 12 months.

Bank of America’s Mariana Perez Mora believes Palantir is ‘uniquely positioned to capture the growing commercial and government demand for AI products.’ Perez Mora rates the stock a ‘buy,’ with a price target of $28, implying a 36% increase from its current price.

On May 7, Citi updated its outlook on Palantir, raising the price target from $23 to $25 while maintaining a ‘neutral’ rating. This change reflects a more optimistic view of the company’s US commercial business and profitability.

Similarly, on May 7, HSBC‘s Stephen Bersey increased his price target for Palantir from $22 to $23, a 4.5% rise, while maintaining a ‘hold’ rating on the stock.

Only one analyst sees PLTR stock above $30

On May 6, ahead of Palantir Technologies’ quarterly report, Wedbush maintained its ‘outperform’ rating and $35 price target on the company. 

The firm anticipated a strong quarter for Palantir, driven by the performance of its US commercial segment.

This rating is a stark contrast to the industry-wide average of $21.89, indicating an increase of 64.78% from the current price level of PLTR stock.

Buy stocks now with eToro – trusted and advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.